Search

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4, programmed cell death protein/ligand 1 are approved for treatment of multiple cancer types. 

The dystroglycan receptor maintains glioma stem cells in the vascular niche

These findings reveal a central role of the DG receptor, not only as a structural element, but also as a critical factor promoting mesenchymal-like GBM

A Novel Missense Mutation Affecting the N-terminal Domain of SAP Protein in X-linked Lymphoproliferative Disease

We have revealed a novel SH2D1A gene mutation in a patient with XLP resulting in fulminant refractory EBV-driven HLH, which is a recognized severe complication

Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial.

Whole genome sequencing of poor and exceptional survivors identified a gain in Chromosome 19 that was exclusive to the exceptional survivors

Family history of cancer and the risk of childhood brain tumors: a pooled analysis of the ESCALE and ESTELLE studies (SFCE)

Our findings support the hypothesis of a familial susceptibility of childhood brain tumors, not due to being a known neurofibromatosis carrier

Melanoma

Melanoma, also known as malignant melanoma, occurs when abnormal skin cells multiply rapidly in an uncontrolled way.

Timo Lassmann

Feilman Fellow; Head, Precision Health Research and Head, Translational Intelligence

Liz Milne

Honorary Emeritus Fellow

Brain Tumour

Brain tumours are the second most common cancer in children (after leukaemia).

Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia

It is now well accepted that germline or de novo genetic alterations predispose to cancer development, especially during childhood. Among them, constitutive trisomy 21, also known as Down syndrome (DS), has been shown to predispose to acute leukemia affecting both the myeloid (ML-DS) and lymphoid (DS-ALL) lineages. ML-DS is associated with a good prognosis compared to children without DS, due in part to a higher sensitivity to conventional chemotherapy.